

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

August 2017

---

Commission File Number: 001-38067

---

**Verona Pharma plc**  
(Exact Name of Registrant as Specified in Its Charter)

---

**3 More London Riverside  
London SE1 2RE UK  
+44 203 283 4200**  
(Address of principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

On August 21, 2017, Verona Pharma plc issued a release notification system announcement in the United Kingdom (the "RNS") disclosing an acquisition by a person discharging managerial responsibilities.

The RNS is furnished herewith as Exhibit 99.1 to this Report on Form 6-K.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**VERONA PHARMA PLC**

Date: August 24, 2017

By: /s/ Jan-Anders Karlsson

Name: Jan-Anders Karlsson, Ph.D.

Title: Chief Executive Officer

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Release Notification System Announcement of Verona Pharma plc, dated August 21, 2017



# Verona Pharma

## PDMR Dealing

August 21, 2017, LONDON — Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on August 17, 2017, Dr. David Ebsworth, Non-Executive Chairman of the Company, purchased 8,130 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 122.5 pence per Ordinary Share. Following the acquisition, Dr. Ebsworth will have an interest in the Company of 125,787 Ordinary Shares, representing 0.12% of the Company’s issued share capital.

The notification of dealing form can be found below.

For further information, please contact:

Verona Pharma plc  
Jan-Anders Karlsson, Chief Executive Officer

Tel: +44 (0)20 3283 4200  
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)  
Aubrey Powell / James White

Tel: +44 (0)20 7496 3000

FTI Consulting (UK Media and Investor enquiries)  
Simon Conway / Natalie Garland-Collins

Tel: +44 (0)20 3727 1000  
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)  
Darcie Robinson

Tel: +1 203-682-8379  
Darcie.Robinson@icrinc.com  
Tel. +1 646-277-1282  
Stephanie.Carrington@icrinc.com

Stephanie Carrington

- |    |   |                        |
|----|---|------------------------|
| 1  | Details of the person discharging managerial responsibilities/person closely associated |                        |
| a) | Name  | David Ebsworth         |
| 2  | Reason for the notification   |                        |
| a) | Position/status   | Non-Executive Chairman |
| b) | Initial notification/Amendment  | Initial notification   |
-

3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	Verona Pharma plc				
b)	LEI	213800EVI6O6J3TIAL06				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 5 pence each				
	Identification code	GB00BYW2KH80				
b)	Nature of the transaction	David Ebsworth purchased 8,130 Ordinary Shares				
c)	Price(s) and volume(s)	<table border="0" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: center; border-bottom: 1px solid black;">Price(s)</th> <th style="text-align: center; border-bottom: 1px solid black;">Volume(s)</th> </tr> </thead> <tbody> <tr> <td style="border-bottom: 1px solid black;">122.5 pence per Ordinary Share</td> <td style="border-bottom: 1px solid black;">8,130 Ordinary Shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	122.5 pence per Ordinary Share	8,130 Ordinary Shares
Price(s)	Volume(s)					
122.5 pence per Ordinary Share	8,130 Ordinary Shares					
d)	Aggregated information	N/A				
	<ul style="list-style-type: none"> <li>• Aggregated volume</li> <li>• Price</li> </ul>					
e)	Date of the transaction	17 August 2017				
f)	Place of the transaction	London Stock Exchange, AIM				

---